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ABSTRACT
Growth arrest-specific 5 (GAS5) lncRNA promotes apoptosis, and its expression 
is down-regulated in breast cancer. GAS5 lncRNA is a decoy of glucocorticoid/related 
receptors; a stem-loop sequence constitutes the GAS5 hormone response element 
mimic (HREM), which is essential for the regulation of breast cancer cell apoptosis. 
This preclinical study aimed to determine if the GAS5 HREM sequence alone promotes 
the apoptosis of breast cancer cells. Nucleofection of hormone-sensitive and 
–insensitive breast cancer cell lines with a GAS5 HREM DNA oligonucleotide increased 
both basal and ultraviolet-C-induced apoptosis, and decreased culture viability and 
clonogenic growth, similar to GAS5 lncRNA. The HREM oligonucleotide demonstrated 
similar sequence specificity to the native HREM for its functional activity and had 
no effect on endogenous GAS5 lncRNA levels. Certain chemically modified HREM 
oligonucleotides, notably DNA and RNA phosphorothioates, retained pro-apoptotic.
activity. Crucially the HREM oligonucleotide could overcome apoptosis resistance 
secondary to deficient endogenous GAS5 lncRNA levels. Thus, the GAS5 lncRNA HREM 
sequence alone is sufficient to induce apoptosis in breast cancer cells, including 
triple-negative breast cancer cells. These findings further suggest that emerging 
knowledge of structure/function relationships in the field of lncRNA biology can 
be exploited for the development of entirely novel, oligonucleotide mimic-based, 
cancer therapies.
INTRODUCTION
Long non-coding RNAs (lncRNAs) are now 
recognized as a major component of the human 
transcriptome, but the vast majority of these molecules 
remain to be functionally annotated [1, 2]. Nonetheless, 
key regulatory roles in fundamental cellular processes are 
already evident for several well characterized lncRNAs [3 
– 5], and dysregulated expression of these may contribute 
to the pathogenesis of major diseases, notably cancer [3, 
6, 7]. Consequently, the lncRNAs may offer new targets 
for the development of novel diagnostics and therapeutics.
The growth arrest-specific 5 (GAS5) gene is of 
particular relevance in this regard. GAS5 encodes lncRNA 
in addition to a diverse range of other non-coding RNAs, 
including small nucleolar RNAs, PIWI-interacting RNAs 
and possibly micro RNAs (miRNAs) [8–10]. GAS5 
lncRNA is down-regulated in multiple cancers [11], 
including breast cancer [12]. In such cancers, clinico-
pathological characteristics show inverse correlations 
with GAS5 lncRNA levels, and low GAS5 lncRNA levels 
are often predictive of poor prognosis [11]. A tumour 
suppressor role for GAS5 lncRNA is further indicated by 
its inhibition of tumour growth in xenograft models of 
breast and other cancers [11, 13].
At the cellular level, GAS5 lncRNA promotes 
growth arrest and/or apoptosis of multiple cell types 
[11], including hormone-sensitive and –insensitive 
breast cancer cells [12–14], which is likely to account 
for its tumour suppressor function. Since the action of 
radiation therapy and many chemotherapeutics depends 
on the engagement of the apoptotic machinery [15, 
16], this is likely to be significant from a therapeutic 
perspective. Indeed, down-regulation of GAS5 lncRNA 
levels attenuates apoptosis induction by a broad range 
of treatments; for most, cell death shows a direct 
quantitative relationship with GAS5 lncRNA levels in 
breast and other cancer cells [14, 17, 18]. Consequently, 
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enhancing cellular GAS5 lncRNA levels in tumour tissue 
may not only suppress the growth of such tumours but 
also enhance tumour cell killing by therapeutic agents, 
thereby improving patient outcomes.
One way to achieve this therapeutic goal may be 
to target the physiological mechanism that mediates the 
accumulation of GAS5 lncRNA levels in growth-arrested 
cells. GAS5 possesses a 5′-terminal oligopyrimidine (5′-
TOP) sequence, therefore its translation is promoted by 
mTOR, which has high activity in actively growing cells 
[8, 19]. Because the GAS5 open reading frame is short 
and does not encode a functional protein, this in turn 
targets transcripts for degradation by nonsense-mediated 
decay (NMD), resulting in low cellular levels of GAS5 
lncRNA [8, 19]. Conversely, inhibition of cell growth 
and mTOR activity prevents the active translation of 
GAS5 transcripts. Since degradation through NMD is 
dependent on active translation of the RNA concerned, 
GAS5 lncRNA accumulates upon growth arrest [8, 19]. 
While mTOR inhibitors increase GAS5 lncRNA levels in 
hormone-sensitive breast cancer cells, they are ineffective 
in triple-negative breast cancer (TNBC) cells and other 
hormone-independent cancer cells [14, 20], so that 
alternative, mTOR inhibitor-independent, approaches are 
required to activate this key pathway across a broad range 
of cancer subtypes.
Several molecular mechanisms of action have 
been proposed for GAS5 lncRNA, which offer 
possibilities in this respect. Firstly, it interacts with 
and riborepresses certain members of the steroid 
nuclear receptor superfamily, and thereby modulates 
the transcription of genes regulating apoptosis and the 
cell cycle. A stem-loop structure within GAS5 lncRNA 
3′-terminal sequence (exon 12 –encoded), which serves 
as a hormone response element mimic (HREM), is 
required for this interaction [21]. Secondly, it can act 
as a miRNA sponge, since it binds to and modulates the 
levels of onco-miR21; a distinct (exon 4-derived) GAS5 
sequence is required for this activity [13]. Functional 
analysis of mutated GAS5 lncRNA sequence has 
revealed that while apoptosis induction in lymphoid 
cells is only partially dependent on the GAS5 HREM 
sequence, more complete dependence is observed 
in breast and prostate cancer cells [22], implicating 
riborepression as the major mechanism by which 
GAS5 lncRNA induces the death of these cells. Novel 
oligonucleotide therapy, based on the GAS5 lncRNA 
HREM sequence, may therefore be feasible, but it is not 
yet clear if this sequence alone is sufficient to mediate 
apoptosis induction in epithelial cells, or if additional 
GAS5 lncRNA sequence is required. In order to address 
these questions, we have examined if the GAS5 HREM 
sequence alone is sufficient to promote the apoptosis of 
breast cancer cells, both basally and upon the application 
of an apoptotic stimulus, and how the resulting cellular 
responses compare with those of mature GAS5 lncRNA.
RESULTS
DNA oligonucleotides corresponding to the 
GAS5 HREM induce apoptosis in breast cancer 
cell lines
Nucleofection of a plasmid encoding mature GAS5 
lncRNA induces apoptosis in hormone-sensitive and 
-insensitive breast cancer cell lines [12 – 14], and wild-
type HREM sequence is required for this activity [22]. 
In initial experiments, we therefore examined if DNA 
oligonucleotides based on the wild-type GAS5 HREM 
sequence alone also induced apoptosis in a range of breast 
cancer cell lines; negative controls were nucleofected with 
DNA oligonucleotides either with stem complementarity 
but lacking the GAS5 HRE consensus (stem loop or SL 
control) or with scrambled GAS5 sequence (Scram control). 
Parallel nucleofection of a plasmid encoding GAS5 lncRNA 
(or empty plasmid vector as the respective control) was 
performed in some experiments, as a positive control.
In hormone-sensitive MCF7 cells, the apoptotic rate 
and culture viability were similar for cells nucleofected 
with either the Scram or SL DNA oligonucleotides 
(Figures 1A & 1B); levels were indistinguishable from 
those of mock-transfected cells (data not shown). 
Nucleofection of the HREM DNA oligonucleotide 
approximately doubled the apoptotic rate (Figure 1A) and 
produced a corresponding decrease in culture viability 
(Figure 1B) relative to the control DNA oligonucleotides. 
The extent of apoptosis induction by the HREM 
oligonucleotide (Figure 1A) was similar to that for MCF7 
cells transfected with a plasmid encoding GAS5 lncRNA 
(Figure 1C), whereas the latter construct produced a more 
sustained loss of short-term culture viability (Figure 1D) 
than the HREM oligonucleotides (Figure 1B). Similar 
results were obtained for the other hormone-sensitive 
cell line, T-47D, studied here. Thus, in this cell line, 
the HREM oligonucleotide produced an approximate 
doubling of the basal apoptotic rate (Figure 1E), similar 
to the GAS5 lncRNA plasmid construct (Figure 1G), and 
a corresponding reduction in culture viability (Figure 
1F) which was less sustained than for the GAS5 lncRNA 
plasmid construct (Figure 1H).
GAS5 lncRNA has previously been shown to 
induce apoptosis in hormone-insensitive breast cancer 
cells in addition to hormone-sensitive cell lines [17, 18]. 
Accordingly, in the TNBC line, MDA-MB-231, the GAS5 
HREM DNA oligonucleotide also increased apoptosis 
(Figure 1I) and reduced culture viability (Figure 1J), 
similar to the effects of GAS5 lncRNA (Figures 1K & 1L).
The GAS5 HREM DNA oligonucleotide reduces 
the clonogenic activity of breast cancer cell lines
To determine the long-term consequences of treatment 
with the HREM oligonucleotide for cell survival, clonogenic 
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growth assays were performed. Transfection of the HREM 
DNA oligonucleotide reduced the colony forming ability 
of MCF7, T-47D and MDA-MB-231 cells by 20 – 30% 
(Figures 2A, 2C & 2E, respectively) i.e., slightly less 
effectively than GAS5 lncRNA (25 – 40% inhibition, 
Figures 2B, 2D & 2F, respectively).
The GAS5 HREM DNA oligonucleotide 
promotes apoptosis induction upon DNA damage 
in breast cancer cell lines
In addition to modulating the basal apoptotic rate, 
GAS5 lncRNA promotes apoptosis induction in breast 
cells by a range of treatments, including chemotherapeutic 
agents and physical stimuli, such as irradiation with UV-C 
light, which activates the DNA damage response [12 – 14]. 
To test whether the HREM oligonucleotide exerts similar 
activity to GAS5 lncRNA in this respect, breast cancer cells 
were nucleofected with either the HREM or control (Scram 
and SL) oligonucleotides and then, after 24 h, cells were 
irradiated with UV-C light at dosages to induce apoptosis 
in ca. 50% cells. Parallel transfections were conducted with 
plasmid constructs ± GAS5 lncRNA, as a positive control. 
Prior transfection with the HREM oligonucleotide enhanced 
UV-C-induced apoptosis and correspondingly decreased 
culture viability in MCF7 (Figures 3A & 3B, respectively), 
T-47D (Figuress 3E & 3F, respectively) and MDA-MB-231 
(Figures 3I & 3J, respectively) cells. In general, the 
magnitude of these effects were similar to those of GAS5 
lncRNA (Figures 3C & 3D for MCF7, Figures 3G & 3H for 
T-47D, and Figures 3K & 3L for MDA-MB-231), further 
highlighting the similar activities of the GAS5 HREM and 
GAS5 lncRNA sequences.
Sequence specificity of GAS5 HREM action
Two guanine-containing pairs (G549 and G559) 
within the HREM of GAS5 lncRNA are essential for 
Figure 1: Effect of the GAS5 HREM DNA oligonucleotide on the basal survival of breast cancer cells. Cells (n = 4 
cultures) were transfected with the GAS5 HREM DNA oligonucleotide (HREM) or scrambled (scram) or stem loop (SL) control DNA 
oligonucleotides; transfections were also conducted with the plasmids pcDNA3.GAS5 (encodes mature GAS5 lncRNA) and pcDNA3 
(empty control vector) as controls. Cells were harvested at 24 h post-transfection for assessment of cell survival, and re-plated for re-
assessment after a further 48 h. The GAS5 HREM oligonucleotide increased apoptosis and decreased cell viability in MCF7 (panels A & 
B, respectively), T-47D (panels E & F, respectively) and MDA-MB-231 (panels I & J, respectively) cells, similar to the action of GAS5 
lncRNA (panels C & D, respectively for MCF7 cells; G & H, respectively for T-47D cells; and K & L, respectively, for MDA-MB-231 
cells). *P < 0.05, **P < 0.01 and ***P < 0.001 versus scram and SL for HREM or versus pcDNA3 for pcDNA3.GAS5 (two-way ANOVA 
and Bonferroni’s MCT).
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its interaction with the DNA binding domain of the GR 
[22]. Mutation of one of these (G549A) is sufficient 
to inhibit the GR/GAS5 lncRNA interaction and to 
prevent the induction of apoptosis by GAS5 lncRNA 
in breast and prostate cell lines [22]. We therefore 
examined if induction of apoptosis by the GAS5 HREM 
oligonucleotide exhibited similar sequence specificity by 
employing a modified DNA oligonucleotide carrying the 
equivalent mutation. In MCF7 cells, the oligonucleotide 
corresponding to the wild-type GAS5 HREM sequence 
induced apoptosis (Figure 4A) and reduced short-term 
culture viability (Figure 4B) compared with the SL control 
oligonucleotide, whereas the effects of the oligonucleotide 
with mutated HREM sequence were indistinguishable 
from those of the SL control (Figures 4A & 4B).
The GAS5 HREM oligonucleotide restores 
cell death inhibited by low endogenous GAS5 
lncRNA expression
Endogenous GAS5 lncRNA levels are reduced 
in breast tumour versus adjacent normal tissue and in 
hormone-insensitive versus hormone-sensitive breast 
cancer cells [12 – 14]. In hormone-sensitive breast cancer 
Figure 2: Effect of the GAS5 HREM DNA oligonucleotide on the clonogenic activity of breast cancer cells. Cells (n = 
4 cultures) were transfected with the GAS5 HREM DNA oligonucleotide (HREM) or scrambled (scram) or stem loop (SL) control DNA 
oligonucleotides; transfections were also conducted with the plasmids pcDNA3.GAS5 (encodes mature GAS5 lncRNA) and pcDNA3 
(empty control vector) as positive controls. Cells were harvested at 24 h post-transfection and an equal portion of each re-plated at low cell 
density for assessment of colony forming ability; data are expressed relative to the respective control. The GAS5 HREM oligonucleotide 
reduced the number of colonies formed by MCF7 (panel A), T-47D (panel C) and MDA-MB-231 (panel E) cells, similar to the action of 
GAS5 lncRNA (panels B, D & F, respectively). *P < 0.05 and **P < 0.01 versus SL for HREM or versus pcDNA3 for pcDNA3.GAS5 
(Student’s t-test).
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cells, siRNA-mediated knockdown of GAS5 lncRNA 
attenuates responses to a range of pro-apoptotic treatments, 
including UV-C irradiation [13, 14]. To investigate if 
the HREM DNA oligonucleotide can overcome such 
resistance consequent upon low endogenous GAS5 
lncRNA levels, we used siRNA to silence GAS5 
expression in MCF7 cells prior to transfection of the 
HREM (and control) oligonucleotide, then examined 
cellular responses ± irradiation with UV-C light.
The GAS5 siRNA markedly reduced GAS5 lncRNA 
levels immediately prior to oligonucleotide nucleofection 
(Figure 5A) but this had no effect on basal apoptosis 
(Figure 5B) or cell survival (Figure 5C) at 20 h post-
transfection of either the SL or HREM oligonucleotide; the 
HREM oligonucleotide produced the expected changes of 
similar magnitude in these parameters, irrespective of the 
endogenous GAS5 lncRNA levels. Cells were then treated 
± UV-C light then studied after a further 48 h culture; at 
this time point, the mock-irradiated controls demonstrated 
a similar pattern of change in apoptosis (Figure 5D) and 
cell viability (Figure 5E) as at 20 h post-transfection 
(in comparison to Figures 5B & 5C, respectively), 
notwithstanding the expected decline in the proportion 
of cells undergoing active apoptosis. As regards UV-C 
irradiation, prior knockdown of GAS5 lncRNA clearly 
attenuated apoptosis induction (Figure 5F) and loss of 
culture viability (Figure 5G), as judged from the responses 
of cells which had received the SL control oligonucleotide. 
Crucially however, prior transfection with the HREM 
oligonucleotide enhanced UV-C-induced apoptosis (Figure 
5F) and the associated loss of culture viability (Figure 5G), 
irrespective of the level of endogenous GAS5 lncRNA. 
Notably, the proportions of apoptotic (and viable) cells 
were similar for the NC-HREM and #4-HREM treatment 
Figure 3: Effect of the GAS5 HREM DNA oligonucleotide on UV-C-induced cell death of breast cancer cells. Cells (n = 
4 cultures) were transfected with the GAS5 HREM DNA oligonucleotide (HREM) or scrambled (scram) or stem loop (SL) control DNA 
oligonucleotides; transfections were also conducted with the plasmids pcDNA3.GAS5 (encodes mature GAS5 lncRNA) and pcDNA3 
(empty control vector) as positive controls. Cells were harvested at 24 h post-transfection, irradiated with UV-C light and re-plated for 
assessment of cell survival after a further 48 h. The GAS5 HREM oligonucleotide increased UV-C induced apoptosis and the associated loss 
of cell viability in MCF7 (panels A & B, respectively), T-47D (panels E & F, respectively) and MDA-MB-231 (panels I & J, respectively) 
cells, similar to the action of GAS5 lncRNA (panels C & D, respectively for MCF7 cells; G & H, respectively for T-47D cells; and K & 
L, respectively, for MDA-MB-231 cells). *P < 0.05, **P < 0.01 and ***P < 0.001 versus scram and SL for HREM or versus pcDNA3 for 
pcDNA3.GAS5 (one-way ANOVA and Bonferroni’s MCT).
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groups, demonstrating that the HREM oligonucleotide can 
prevent the attenuation of cell death caused by reduced 
GAS5 lncRNA levels.
The GAS5 HREM DNA oligonucleotide has no 
effect on endogenous GAS5 lncRNA levels
GAS5 lncRNA exerts pro-apoptotic effects in 
breast cancer cell lines as does the GAS5 HREM DNA 
oligonucleotide (Figures 1A, 1E & 1I). To address the 
postulate that the GAS5 HREM oligonucleotide may 
exert its pro-apoptotic activity via changes in endogenous 
levels of GAS5, RT-qPCR analysis was performed 
on MCF7, T-47D and MDA-MB-231 cell lines at 20 h 
post-transfection of control and GAS5 HREM DNA 
oligonucleotides. In all cases, GAS5 lncRNA levels were 
similar between cells transfected with the GAS5 HREM 
and control oligonucleotides (Figure 6), excluding an 
indirect role for GAS5 lncRNA per se in GAS5 HREM 
oligonucleotide action.
Chemically modified GAS5 HREM 
oligonucleotides also induce apoptosis
Since experiments so far had employed a HREM 
DNA oligonucleotide, although the naturally occurring 
HREM is present within lncRNA, we wished to examine 
the efficacy of a HREM RNA oligonucleotide. Since RNA 
Figure 4: Sequence specificity of the GAS5 HREM DNA oligonucleotide. MCF7 cells (n = 5 cultures) were transfected with 
either the wild-type GAS5 HREM DNA oligonucleotide (HREMwt), a mutated GAS5 HREM DNA oligonucleotide (HREMG549A) or the 
standard stem loop (SL) control DNA oligonucleotides. Cells were harvested at 20 and 48 h post-transfection, for assessment of cell 
survival. Only the HREMwt oligonucleotide increased apoptosis (panel A) and decreased cell viability (panel B) relative to the SL control 
oligonucleotide. ***P < 0.001 versus SL, and ^P < 0.05, ^^P < 0.01 and ^^^P < 0.001 for HREMG549A versus HREMwt (two-way ANOVA 
and Bonferroni’s MCT).
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Figure 5: Effect of the GAS5 HREM DNA oligonucleotide on basal and UV-C-induced cell death after silencing of 
endogenous GAS5 expression in MCF7 cells. Cells (n = 4 cultures) were transfected with either GAS5 siRNA (GAS5#4; targets exon 
12 sequence) or negative control (NC) siRNA and, after 24 h, transfected with either the GAS5 HREM DNA oligonucleotide (HREM) or 
stem loop (SL) control DNA oligonucleotides. After 20 h, cells were irradiated with UV-C light, then plated for assessment of cell survival 
after a further 48 h. The GAS5#4 siRNA markedly reduced GAS5 lncRNA levels at 24 h post-transfection (panel A) i.e., immediately 
prior to nucleofection of DNA oligonucleotides. The HREM oligonucleotide induced apoptosis (panel B) and decreased culture viability 
(panel C) at 20 h post-transfection, irrespective of endogenous GAS5 lncRNA levels; a similar pattern was found for apoptosis (panel D) 
and culture viability (panel E) in mock-irradiated controls (i.e. at 68 h post-oligonucleotide transfection). Silencing of GAS5 attenuated 
UV-C induced apoptosis (panel F) and the associated loss of culture viability (panel G) at 48 h post-irradiation, but had no effect cell death 
induction by the HREM oligonucleotide. Panel A: ***P < 0.001 versus cells transfected with NC siRNA (Student’s t-test). Panels B – H: 
*P < 0.05, **P < 0.01 & ***P < 0.001 versus cells transfected with SL oligonucleotide; and ^P < 0.05 versus cells transfected with NC 
siRNA (one-way ANOVA and Bonferroni’s MCT).
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is prone to degradation, especially within exonuclease-
rich cellular environments, we additionally examined 
several oligonucleotides with chemical modifications 
to the backbone that improve stability in vivo [23], i.e., 
phosphorothioate RNA [RNA(PT)] and locked nucleic 
acid (LNA) oligonucleotides. In these screening studies, 
nucleofection of both unmodified RNA and RNA(PT) 
HREM oligonucleotides stimulated the basal apoptosis of 
MCF7 cells, whereas the LNA oligonucleotide was less 
effective and did not reach statistical significance (Figure 
7A). Short-term culture viability was also reduced by 
the GAS5 HREM RNA and RNA(PT) oligonucleotides 
(Figure 7B). As regards long-term survival however, only 
the GAS5 HREM RNA(PT) oligonucleotide was able 
to reduce the colony forming ability of MCF7 cells to a 
degree that was statistically significant (Figure 7C).
Given these findings, it was of interest to 
determine if a phosphorothioate DNA [DNA(PT)] form 
of the GAS5 HREM also induces apoptosis in MCF7 
cells. In addition, a morpholino HREM oligonucleotide 
was included in this screen, as the utility of this chemical 
modification has already been demonstrated for other 
types of therapeutic oligonucleotide (notably antisense 
oligonucleotides) [23]. Both chemically modified forms 
of the HREM DNA oligonucleotide induced apoptosis 
(Figure 7D) and reduced short-term viability (Figure 
7E) in MCF7 cells. However, only the DNA(PT) 
oligonucleotide reduced the long-term survival of MCF7 
cells to a degree that was statistically significant (Figure 
7F). Notably, the extent of this reduction was similar 
to that of the RNA(PT) form of the GAS5 HREM 
oligonucleotide (compare Figures 7C & 7F).
DISCUSSION
Currently, there is a major need to develop new 
targeted therapies for breast and other cancers. In the 
Figure 6: Effect of the GAS5 HREM DNA oligonucleotide on endogenous GAS5 lncRNA levels in breast cancer cells. Cells 
(n = 4 cultures) were transfected with either the GAS5 HREM DNA oligonucleotide (HREM) or scrambled (scram) or stem loop (SL) control 
DNA oligonucleotides and cells were harvested at 24 h post-transfection for determination of GAS5 lncRNA levels by RT-qPCR. The GAS5 
HREM oligonucleotide had no effect on GAS5 lncRNA levels in MCF7 (panel A), T-47D (panel B) and MDA-MB-231 (panel C).
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case of breast cancer, this is especially true for hormone-
insensitive forms of disease, such as TNBC, which is 
often characterised by highly malignant behaviour and 
resistance to conventional chemotherapy [24]. Much effort 
is being focussed on the development of drugs which 
directly target oncoproteins [24, 25], while increasing 
knowledge of the importance of lncRNAs in health and 
disease may offer opportunities for the design of entirely 
novel oligonucleotide-based oncotherapies. Towards 
this goal, we have exploited recent knowledge regarding 
the structure/function relationship of the relatively well 
characterized GAS5 lncRNA [22], an apoptosis-promoting 
molecule and putative tumour suppressor [11], and 
demonstrate here for the first time that oligonucleotides 
based on the HREM sequence alone are sufficient to 
induce the apoptosis of breast cells. This work is of more 
general significance, since it provides the first proof-of-
principle of using partial sequences to mimic the action 
of tumour suppressive lncRNA molecules and, as such, 
points to an innovative approach for oligonucleotide-based 
oncotherapies of potential clinical importance.
GAS5 lncRNA levels are down-regulated in a 
wide range of tumours, including breast cancer; in many 
cancers low levels of expression are prognostic of poor 
patient survival [11]. The basis for this tumour suppressor 
function has been ascribed to the apoptosis-promoting 
activity of GAS5 lncRNA, which has itself been shown 
to reside within the HREM portion of the GAS5 lncRNA 
molecule in breast and other cells [21, 22]. The present 
study, which employs independent assays of apoptotic 
morphology, short-term culture viability and long-term 
clonogenic survival, clearly demonstrates that the HREM 
portion alone of the GAS5 lncRNA molecule induces 
cell death in three different breast cancer cell lines, 
including both hormone-sensitive and –insensitive breast 
cancer cells. Notably, for all cells, the extent of apoptosis 
Figure 7: Effect of chemically modified GAS5 HREM RNA and DNA oligonucleotides on the basal survival of MCF7 
cells. Cells (n = 4 cultures) were transfected with a range of chemically modified GAS5 HREM and corresponding stem loop (SL) control 
oligonucleotides comprising: unmodified RNA (RNA-HREM & RNA-SL); phosphorothioate RNA (RNA(PT)-HREM & RNA(PT)-SL); 
locked nucleic acid (LNA-HREM & LNA-SL); phosphorothioate DNA (DNA(PT)-HREM & DNA(PT)-SL); and morpholinos (morph-
HREM & morph-SL). Cells were harvested at 20 h post-transfection for assessment of cell survival, and an equal portion of each re-plated 
at low cell density for assessment of colony forming ability; the latter data are expressed relative to the respective control. Of the RNA-
based oligonucleotides, the LNA-HREM effect did not reach statistical significance but both the RNA-HREM and the RNA(PT)-HREM 
oligonucleotides increased apoptosis (panel A) and decreased cell viability (panel B); the inhibition of clonogenic growth reached statistical 
significance for only the RNA(PT)-HREM oligonucleotide (panel C). Both the DNA(PT)-HREM and morph-HREM oligonucleotides also 
increased apoptosis (panel D) and decreased cell viability (panel E), but the inhibition of clonogenic growth reached statistical significance 
for only the DNA(PT)-HREM (panel F). *P < 0.05, **P < 0.01 and ***P < 0.001 versus the corresponding SL control (one-way ANOVA 
and Bonferroni’s MCT).
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induction and inhibition of growth were similar for both 
the GAS5 HREM oligonucleotide and GAS5 lncRNA.
The GAS5 HREM oligonucleotide also enhanced 
the action of an external apoptotic stimulus, UV-C 
irradiation. For both the partial and full length GAS5 
lncRNA sequences, this effect was additive rather than 
synergistic, as previously noted for the latter sequence 
[12, 14]. Of direct clinical relevance, reduced endogenous 
GAS5 lncRNA expression, such as occurs in breast 
cancer and many other tumours [11 – 14], attenuates 
cellular responses to apoptotic inducers, including 
UV-C and various chemotherapeutic agents [13, 14]; 
the GAS5 HREM was able to restore breast cancer cell 
sensitivity, as demonstrated here for UV-C irradiation. 
Thus in cancers with deficient GAS5 expression, the GAS5 
HREM oligonucleotide may have therapeutic potential, 
not only by acting as an apoptotic inducer per se, but 
also by restoring the effectiveness of more conventional 
oncotherapies on therapy-resistant cancer cells.
An important question relates to the mechanism of 
action of the GAS5 HREM oligonucleotide in promoting 
the apoptosis of breast cancer cells. Our current working 
hypothesis is that the partial HREM sequence acts as a 
decoy for members of the steroid hormone nuclear receptor 
superfamily, as has been demonstrated for GAS5 lncRNA 
[21, 22]. In order to test this hypothesis we examined the 
effect of a potentially inactivating mutation in the HREM 
on its cytotoxic effects. These experiments demonstrate 
that the HREM oligonucleotide has identical sequence 
specificity to GAS5 lncRNA. Thus, mutation of a single 
base (G549A) of the HREM of GAS5 lncRNA diminishes 
steroid receptor binding and ablates apoptosis induction in 
breast cancer cells [22], and an identical mutation of the 
GAS5 HREM oligonucleotide also prevents its induction 
of apoptosis in MCF7 cells (Figure 4), indicating that the 
mechanism of induction of apoptosis in breast cancer cells 
by the HREM is the same as that of GAS5 lncRNA. It is 
as yet unknown which particular member(s) of the steroid 
hormone nuclear receptor superfamily interact with GAS5 
lncRNA in breast cells, particularly in relation to apoptosis 
induction; consequently, we have been unable to address 
this issue for the GAS5 HREM oligonucleotide. In this 
regard, the GAS5 HREM does not interact with estrogen 
receptors [21, 22], which are crucial for mediating pro-
survival signalling by estrogen in breast cells [26]. While 
the GAS5 HREM interacts with progesterone receptor 
[21, 22], this interaction is unlikely to play a major role 
in breast cancer cell survival, since both GAS5 lncRNA 
[14] and the GAS5 HREM sequence induce apoptosis in 
TNBC cells which are devoid of progesterone receptors. 
On the other hand, a more indirect mechanism of action 
for the GAS5 HREM oligonucleotide, centring on 
endogenous GAS5 lncRNA per se, can be excluded, since: 
i. cellular levels of the latter were unperturbed following 
transfection of the GAS5 HREM oligonucleotide; and ii. 
siRNA-mediated silencing of GAS5 lncRNA had no effect 
on the apoptosis-inducing activity of the GAS5 HREM 
oligonucleotide in MCF7 cells.
These findings prove that for GAS5 lncRNA, 
it is feasible to employ a partial sequence to mimic a 
desirable function of the parental lncRNA and thereby 
point to the possibility of novel oligonucleotide mimic-
based oncotherapeutic approaches. With this in mind, 
a range of commonly used chemical modifications 
which are known to improve oligonucleotide stability 
in vivo [23], were tested for the HREM oligonucleotide 
in functional assays. Following nucleofection, most 
modified HREM oligonucleotides were able to induce 
apoptosis and decrease short-term culture viability, 
although this effect was not statistically significant for the 
locked nucleic acid form. In terms of inhibition of long-
term cell survival, phosphorothioate forms of RNA and 
DNA oligonucleotides appeared optimal. These findings 
indicate that certain, but not all, modifications to the 
oligonucleotide backbone are well tolerated in functional 
terms by the GAS5 HREM oligonucleotide.
Mimic oligonucleotides may have widespread 
applicability as our understanding of the structure/
function relationships of lncRNA molecules increases. 
A particular advantage of such therapies is the ability to 
mimic the activity of tumour suppressor genes, which 
are often down-regulated in tumours, whereas current 
protein-targeted, drug development approaches are biased 
towards the inhibition of oncogenic proteins, which are 
typically overexpressed in tumours. Furthermore, the 
effectiveness of partial sequences, as seen above, makes 
oligonucleotide-based approaches more amenable, 
since these are inherently less complex and therefore 
more practical clinically than gene therapy approaches. 
Examples of other therapeutic approaches that exploit 
emerging knowledge of lncRNA biology and are 
currently under development include siRNA, other 
RNAi and antisense oligonucleotide approaches for 
targeting oncogenic lncRNAs, antagoNAT antisense 
oligonucleotides for targeting antisense lncRNAs to up-
regulate specific mRNAs/proteins, and small molecule 
inhibitor (including oligonucleotides) approaches [23, 27–
29]; the oligonucleotide mimic approach proposed here is 
likely to be compatible with and complementary to these. 
Indeed, the challenges for clinical translation, in terms of 
in vivo stability, tumour delivery and cellular uptake, for 
example, are likely to be similar for all these technologies 
and are currently the focus of active investigation.
MATERIALS AND METHODS
Cell lines and culture conditions
This study employed hormone-sensitive (MCF7 
and T-47D) and –insensitive (MDA-MB-231; TNBC 
cells) breast cancer cell lines. All cultures were generated 
from secondary stocks of cells which had been frozen 
Oncotarget11www.impactjournals.com/oncotarget
down within two weeks receipt from ATCC-LGC 
Promochem (Teddington, Middlesex, UK), and cultures 
were passaged for a maximum period of eight weeks 
before replacement with fresh cell stocks. Culture 
medium was R-10 medium, comprising RPMI-1640 
supplemented with 2 mM L-glutamine, 1 mM sodium 
pyruvate, 10 mM HEPES, 10% fetal bovine serum and 
50 μg/ml gentamicin, and cells were cultured at 37 °C 
in a humidified incubator with 5% CO2. Serum was 
from Labtech International Ltd (Uckfield, UK) and the 
remaining cell culture reagents were from Sigma-Aldrich 
Company Ltd (Gillingham, UK).
Nucleofection of oligonucleotides and  
plasmid DNA
DNA oligonucleotides (Eurofins Genomics, 
Ebersberg, Germany) were studied in the majority of 
experiments and comprised the wild-type GAS5 HREM 
sequence (5′- CAGTGGTCTTTGTAGACTGCCTG-3′), 
a mutated GAS5 HREM (5′- 
CAGTAGTCTTTGTAGACTGCCTG -3′), a control 
sequence which retains stem complementarity but 
lacks the GAS5 HRE consensus (stem loop control; 5′- 
CTGATGGTCTTTGTAGACCATCA-3′) and scrambled 
sequence (5′- TGTTGGCTTGTCACGCATGCGTCT-3′). 
Equivalent stem loop control and wild-type GAS5 HREM 
sequences were also employed in experiments with 
RNA oligonucleotides (Eurofins Genomics, Ebersberg, 
Germany), DNA and RNA phosporothioate-modified 
oligonucleotides (GE Healthcare Dharmacon Inc, 
Little Chalfont, UK) and morpholino oligonucleotides 
(Gene Tools LLC, Philomath, USA). Sequences of 
locked nucleic acid oligonucleotides (Exiqon, Vedbaek, 
Denmark) containing selective phosphorothioate backbone 
modifications (as indicated by *) were: 5′-C+T+G+A+T
+G*G*T*C*T*T*T*G*T+A+G+A+C+C*A*T*C*A-3′ 
for the stem loop control; and C+A+G+T+G+GT*C*T*
T*T*G*T*A*G+A+C+T+G+C*C*T*G-3′ for the GAS5 
HREM. Cells (2 × 106 in 0.1 ml Ingenio electroporation 
solution [Mirus Bio LLC, Madison, WI, USA]) were 
nucleofected with 5 pmol oligonucleotide or 2 μg 
plasmid (either pcDNA3/GAS5—encodes mature GAS5 
lncRNA—or empty pcDNA3 vector as control; positive 
control experiments) using programmes E-014, X-005 
and X-013 for MCF7, T-47D and MDA-MB-231 cells, 
respectively, and cells were plated in 3 ml R-10 medium 
in 6-well plates.
RNA interference by siRNA
MCF7 cells were transfected with Ambion Silencer 
Select GAS5 siRNA (product code n272331; targets exon 
12; Life Technologies, Paisley, UK) or negative control 
(NC) siRNA (product code AM4611) using HiPerFect 
reagent (Qiagen, Crawley, UK) and a fast forward 
protocol. This particular GAS5 siRNA (termed GAS5 
siRNA #4) has previously been shown to silence GAS5 
expression in MCF7 cells using an RNAiFect protocol 
[14]. Briefly, trypsinized cells (2 × 105) were seeded in 2.3 
ml R-10 medium per well of a 6-well plate. Complexes 
were prepared by mixing 12 pmol siRNA in 0.1 ml Opti-
MEM-I medium with 12 μl HiPerFect reagent and, after 
15 min, these were added to cells. Cells were then cultured 
for 20 – 24 h prior to nucleofection with the indicated 
oligonucleotides.
Induction of cell death and cell survival assays
At 20 h post-nucleofection with oligonucleotides, 
cells were trypsinized and resuspended at 2 × 105 cells/ml 
in R-10 medium. A sample was taken for RNA isolation, 
and cells were routinely seeded at 1.6 × 105 cells/well of 
a 12-well plate. In experiments employing ultraviolet-C 
(UV-C) irradiation for apoptosis induction, this was 
performed immediately prior to plating, as described 
elsewhere [17]; the dose used was 40 J/m2 for all cell 
lines; controls were mock-irradiated. Cells were cultured 
for a further 48 h, then adherent cells were trypsinized 
and combined with non-adherent cells for analysis of 
parameters of cell survival.
Apoptosis was routinely determined by assessment 
of nuclear morphology of cells by fluorescence 
microscopy, after staining with acridine orange (25 μg/
ml); cells containing condensed or fragmented chromatin 
were scored as apoptotic. Cell viability was determined 
by dye-exclusion assay by counting of nigrosin blue 
(0.1% (w/v)) stained samples using a haemocytometer 
and light microscopy. To determine long-term survival 
of cells, a clonogenic assay was performed: cells were 
replated in R-10 medium supplemented with 10 % (v/v) 
cell-conditioned medium in 6-well plates, cultured for 3 
weeks and the number of colonies formed was determined 
post-staining with crystal violet.
Real time RT-PCR (RT-qPCR)
Total RNA was isolated with TRIzol, DNase-
treated, then reverse transcribed by random hexamer 
priming using SuperScript II Reverse Transcriptase [14]. 
Real-time PCR was conducted on the resulting cDNA 
using a SensiFast Probe Hi-ROX kit (Bioline, London, 
IK) and TaqMan Gene Expression Assays (assay codes 
Hs99999901_m1 for 18S and Hs03464472_m1 for 
GAS5; Life Technologies, Paisley, UK); assays usually 
contained 10 ng sample cDNA in a final volume of 25 
μl and were run on an ABI Prism Sequence Detection 
System model 7000. Standards (0.2 – 60 ng cDNA 
from untransfected MCF7 cells) were included with 
each assay; the resulting standard curves of threshold 
cycle (CT) value versus log input standard cDNA were 
used to calculate input amounts of samples from their 




Data are presented as the mean ± SEM; the number 
of observations (n) refers to different transfected samples, 
each from a separate culture of cells. Data analysis was 
either by an unpaired Student’s t-test (when comparing 
two groups only), by one-way analysis of variance, with 
Bonferroni’s multiple comparison test (MCT), or by 
two-way analysis of variance, with Bonferroni’s post 
tests, as indicated in the text. Homogeneity of variance 
was checked by Bartlett’s test and, where necessary, data 
were transformed (log or square root) prior to analysis. 
Statistical analyses were performed using GraphPad 
Prism v4.03.
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